MicroRNA-21 in Renal Aging

描述（由申请人提供）：年龄（100 - 60岁）与急性肾损伤（AKI）后死亡率增加相关，幸存者患有慢性肾脏疾病，每年需要花费100亿美元进行透析。从AKI到肾功能恢复失败和CKD的潜在机制的组成部分已经通过包括缺血再灌注损伤在内的动物模型被确定。细胞凋亡、炎症和细胞外基质沉积增加导致肾纤维化和肾功能衰竭。促炎和促纤维化信号的持续激活是这一过程的重要介质。目前尚不清楚为什么老年人在AKI后恢复延迟、不完全或缺失的风险增加。NF-kappaB通路已被确定为人类和啮齿动物中与年龄相关的转录变化的激活因子，并被认为介导组织损伤后GS和TIF的发展。微rna最近被发现在协调NF-kappaB激活的凋亡和促纤维化反应中发挥重要作用。microRNAs （miRs）是一种小RNA分子（长19-22个核苷酸），通过与靶mrna的部分互补来协调基因表达途径。它们是一个特别有吸引力的研究途径，因为它们具有作为可以调节分子途径的长效药物的治疗潜力。我们的初步数据显示，年轻成年miR-21敲除小鼠的缺血再灌注损伤恢复延迟。此外，miR-21抑制培养的肾上皮细胞的凋亡。由于我们在衰老过程中检测到miR-21在肾脏中的表达增加，我们假设这种增加的miR-21表达通过抑制NF-kappaB途径的成分以及与p53和tgf - β信号的串扰，在损伤响应中起保护作用，阻止凋亡和促纤维化途径的激活。我们建议通过检查miR-21缺失小鼠的肾功能、组织学变化和已知介导IR损伤的细胞机制，来确定miR-21缺失是否会改变与衰老相关的缺血再灌注损伤的反应。此外，我们将使用全基因组表达谱和系统生物学方法来比较转录网络结构的模式，定义年龄相关变化的潜在机制以及miR-21在肾对IR损伤反应中的调节作用。我们预计缺乏miR-21的老年小鼠将比具有完整miR-21调节机制的年轻小鼠及其野生型配偶表现出更高的缺血再灌注易感性。证明miR-21的这种保护关系将开启这种微rna可用于治疗的可能性。

DESCRIPTION (provided by applicant): Age (>60yrs) is associated with increased mortality after acute kidney injury (AKI) with survivors being left with chronic kidney disease and on dialysis costing $10 billion per year. Components of the underlying mechanism that lead from AKI to failure to recover kidney function and CKD have been identified using animal models including ischemia-reperfusion injury. Increased apoptosis, inflammation and deposition of extracellular matrix result in renal fibrosis and renal failure. Persistent activation of pro-inflammatory and pro-fibrotic signals are important mediators of this process. It is not understood well why older individuals are at increased risk for delayed, incomplete or absent recovery after AKI. The NF-kappaB pathway has been identified as an activator of age-related transcriptional changes in human and rodents and is thought to mediate development of both GS and TIF following tissue injury. Micro-RNAs have recently been found to play an important role in coordinating the apoptotic and pro-fibrotic response to NF-kappaB activation. microRNAs (miRs), are small RNA molecules (19-22 nucleotides long) that coordinate pathways of gene expression via partial complementary to target mRNAs. They are a particularly attractive avenue for investigation because of their therapeutic potential as long-lasting drugs that can modulate molecular pathways. Our preliminary data show delayed recovery from ischemia-reperfusion injury in young adult miR-21 knockout mice. In addition, miR-21 inhibits apoptosis in cultured renal epithelial cells. Because we detected increasing miR-21 expression in the kidney during aging, we hypothesize that this increased miR-21 expression plays a protective role that prevents activation of the apoptotic and pro-fibrotic pathway activation in response to injury through inhibiting components of the NF-kappaB pathway and crosstalk with p53 and TGF-beta signaling. We propose to determine whether loss of miR-21 alters the response to ischemia-reperfusion injury associated with aging by examining renal function, histologic changes and cellular mechanisms known to mediate IR injury in miR-21 null mice. Furthermore, we will define the underlying mechanism of age-associated changes and its regulation by miR-21 in the renal response to IR injury using genome-wide expression profiling and a systems biology approach to compare patterns of transcriptional network structures. We expect that old mice lacking miR-21 will exhibit increased susceptibility to ischemia-reperfusion than young mice and their wildtype litter-mates with an intact miR-21 regulatory machinery. Demonstration of this protective relationship for miR-21 will open up the possibility that this micro-RNA could be used therapeutically.